JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopamine-containing neurons, but the molecular pathways underlying its pathogenesis remain uncertain. Here, we show that by eliminating c-Jun N-terminal kinases (JNKs) we can prevent neurodegeneration and improve motor function in an animal model of PD. First, we found that c-Jun is activated in dopaminergic neurons from PD patients and in the 1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine (MPTP) mouse model of PD. Examination of various JNK-deficient mice shows that both JNK2 and JNK3, but not JNK1, are required for MPTP-induced c-Jun activation and dopaminergic cell demise. Furthermore, we have identified cyclooxygenase (COX) 2 as a molecular target of JNK activation and demonstrated that COX-2 is indispensable for MPTP-induced dopaminergic cell death. Our data revealed that JNK2- and JNK3-induced COX-2 may be a principle pathway responsible for neurodegeneration in PD.

[1]  M. Ross,et al.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  AC Tose.  Cell , 1993, Cell.

[3]  W. Tatton,et al.  Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.

[4]  M. Herkenham,et al.  Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study , 1991, Neuroscience.

[5]  A. Członkowska,et al.  Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. , 2002, International immunopharmacology.

[6]  Elan D. Louis,et al.  Merritt's Neurology , 2001 .

[7]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[8]  M. Kumegawa,et al.  Fluid Shear Stress-induced Cyclooxygenase-2 Expression Is Mediated by C/EBP β, cAMP-response Element-binding Protein, and AP-1 in Osteoblastic MC3T3-E1 Cells* , 2001, The Journal of Biological Chemistry.

[9]  H. Herschman,et al.  Identification of multiple cis‐acting elements mediating the induction of prostaglandin G/H synthase‐2 by phorbol ester in murine osteoblastic cells , 2000, Journal of cellular biochemistry.

[10]  T. Herdegen,et al.  c-Jun N-Terminal Protein Kinase (JNK) 2/3 Is Specifically Activated by Stress, Mediating c-Jun Activation, in the Presence of Constitutive JNK1 Activity in Cerebellar Neurons , 2002, The Journal of Neuroscience.

[11]  L. Mucke,et al.  Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Wagner,et al.  Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation , 1999, Nature Genetics.

[13]  Dong-Kug Choi,et al.  Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Miller,et al.  CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[15]  P. Rakic,et al.  The Jnk1 and Jnk2 Protein Kinases Are Required for Regional Specific Apoptosis during Early Brain Development , 1999, Neuron.

[16]  L. Wodicka,et al.  Regional and strain-specific gene expression mapping in the adult mouse brain. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[18]  D. Wilkin,et al.  Neuron , 2001, Brain Research.

[19]  Peter T Lansbury,et al.  Genetics of Parkinson's disease and biochemical studies of implicated gene products. , 2002, Current opinion in cell biology.

[20]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[21]  P. Lansbury,et al.  Genetics of Parkinson's disease and biochemical studies of implicated gene products. , 2002, Current opinion in genetics & development.

[22]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  David Baltimore,et al.  Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses , 1995, Cell.

[24]  M. Vila,et al.  The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.

[25]  J. Uney,et al.  Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. López-Martín,et al.  The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism , 1998, Journal of Neuroscience Methods.

[27]  J. Mestre,et al.  Redundancy in the Signaling Pathways and Promoter Elements Regulating Cyclooxygenase-2 Gene Expression in Endotoxin-treated Macrophage/Monocytic Cells* , 2001, The Journal of Biological Chemistry.

[28]  M. Beal.  Mechanisms of excitotoxicity in neurologic diseases , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Dirk Bohmann,et al.  Reduced Ubiquitin-Dependent Degradation of c-Jun After Phosphorylation by MAP Kinases , 1997, Science.

[30]  E. Wagner,et al.  The c-Jun N-terminal kinases in cerebral microglia: immunological functions in the brain. , 2002, Biochemical pharmacology.

[31]  G. Pasinetti,et al.  Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions , 1998, Journal of neuroscience research.

[32]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[33]  P. Rakic,et al.  Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene , 1997, Nature.

[34]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.